IntelGenx (TSXV:IGX; OTCQX:IGXT) announced that a decision by the U.S. District Court for the District of Delaware determined that the process used to manufacture IntelGenx’s and Par Pharmaceutical’s buprenorphine/naloxone sublingual film product for the treatment of opiate addiction does not infringe MonoSol Rx U.S. Patent No. 8,900,497.
“This is a great outcome for IntelGenx, confirming that our process for making generic Suboxone film does not infringe the process covered by the 497 patent,” Dr. Horst Zerbe, president and CEO of IntelGenx, said in a statement.
The Delaware Court also rendered a decision in a separate case, which previously resulted in an infringement finding of the MonoSol Rx U.S. Patent No 8,603,514, denying a motion by IntelGenx and Par to reopen the case. Dr. Zerbe said IntelGenx and Par are working on the appeal process.
